The first day of clinical trials for Gleevec, Bud and Yvonne

Interviewee: Bud. Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998. (DNAi Location: Applications > Genes and medicine > drug design > Bud's Story > The first patient)

Yvonne: Now this is the very first day – fact is it's June of '98. I don't have the exact date, is when the clinical trials started and Bud was the first patient to take this and it was 25 milligrams. And there is a picture that was taken of him and Dr. Druker wishing him luck so we're pretty proud of that picture. And then this guy over here, he's showing you what the pill looks like so at that time it was a number but now it's known at Gleevec™. Bud: Yeah STI-571.

chronic myeloid leukemia,sti 571,brian druker,gleevec,location applications,dnai,romine,cml,interviewee,milligrams,yvonne,clinical trials,leukemia,bud,genes,medicine

  • ID: 15042
  • Source: DNALC.DNAi

Related Content

15043. Bloodcount returns to normal with Gleevec, Bud and Yvonne

CML causes an increased production of white blood cells. Bud and Yvonne talk about the breakthrough that brought Bud's white blood cell count back to normal.

  • ID: 15043
  • Source: DNAi

15041. Getting the diagnosis of chronic myeloid leukemia, Bud

Bud recounts receiving the diagnosis that he had chronic myeloid leukemia.

  • ID: 15041
  • Source: DNAi

15056. Approval for Gleevec in record time, Brian Druker

Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process.

  • ID: 15056
  • Source: DNAi

15057. Before and after Gleevec, Brian Druker

Brian Druker talks about the drug he developed as a turning point in the war on cancer.

  • ID: 15057
  • Source: DNAi

15058. The first clinical success with Gleevec, Brian Druker

Brian Druker talks about Bud, the first patient restored to health by Gleevec™.

  • ID: 15058
  • Source: DNAi

15054. Restoring hope with Gleevec, Brian Druker

Brian Druker talks about how Gleevec has restored patients' hope for the future.

  • ID: 15054
  • Source: DNAi

15082. Shutting down cancer with Gleevec, Brian Druker

Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.

  • ID: 15082
  • Source: DNAi

15055. Using DNA science to control CML, Brian Druker

Brian Druker talks about how the drug he designed targets the molecular cause of CML.

  • ID: 15055
  • Source: DNAi

15525. How Gleevec works to alleviate symptoms of myeloid leukemia, 3D animation with basic narration

View the animation to find out how the drug Gleevec™ inhibits the molecular cause of chronic myeloid leukemia.

  • ID: 15525
  • Source: DNAi

16109. Sense of urgency, Brian Druker

Brian Druker talks about sense of urgency.

  • ID: 16109
  • Source: DNAi